how long have glp-1 drugs been around Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review | How GLP-1 Drugs Went From

Gastric inhibitory polypeptide (GIP) and glucagonlike peptide1 (GLP1) are the two primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic cells

Aids sustainable weight management

The hypothesis posits that a systems-based review of GLP-1 RA mechanisms will reveal positive and negative effects across multiple organ systems, providing comprehensive insights into the hormone's physiological impact.This systematic review will assess the appropriateness of GLP-1 RAs in various aforementioned patient health states, shedding light on their potential impacts on comorbidities

Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s)

Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction

Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy.